Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients

Junna Hou; Guohong Liu; Yufen Yuan; Dong Wang; Pengfei Jiao; Lihua Xing; Yunbao Pan

doi:10.18632/oncotarget.22146

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients

Junna Hou, Guohong Liu, Yufen Yuan, Dong Wang, Pengfei Jiao, Lihua Xing and Yunbao Pan _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:97504-97515. https://doi.org/10.18632/oncotarget.22146

Metrics: PDF 1853 views | HTML 1981 views | ?

Abstract

Junna Hou1,*, Guohong Liu2,*, Yufen Yuan3,*, Dong Wang4, Pengfei Jiao1, Lihua Xing1 and Yunbao Pan4,5

1Department of Pulmonary Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, China

2School of Materials Science and Engineering and School of Electronics and Information Technology, Sun Yat-Sen University, Guangzhou, Guangdong 510275, China

3Department of Pathology, Anyang Tumor Hospital, Anyang, Henan 455000, China

4Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430071, China

5Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510080, China

*These authors contributed equally to this work and should be considered as co-first authors

Correspondence to:

Yunbao Pan, email: [email protected]

Lihua Xing, email: [email protected]

Keywords: breast cancer; lung cancer; Jab1; biomarkers; immunohistochemistry

Received: July 06, 2017 Accepted: August 29, 2017 Published: October 27, 2017

ABSTRACT

Adjuvant chemotherapy has been established as standard treatment for advanced cancer among multidisciplinary therapies. A simple and instructive biomarker for therapeutic response and recurrence is needed to evaluate the therapeutic effect. Jab1/COPS5 level has been shown to be associated with tumor progression and poor outcomes in many types of cancer patients. This study aims to further evaluate the clinical and prognostic value of Jab1/COPS5 level as a biomarker in lung and breast cancer patients receiving adjuvant chemotherapy. In this study, data of 88 lung cancer and 76 breast cancer patients were retrospectively collected and analyzed to identify the relationship between the Jab1/COPS5 level and the clinical progression and outcome of these patients. Lung cancer patients with increased Jab1/COPS5 level tend to be non-responsive to chemotherapy. Relapsed breast cancer patients had an increased Jab1/COPS5 level and breast cancer patients with increased Jab1/COPS5 level had significantly shorter disease-free survival and overall survival. In a multivariate survival analysis, histological type and Jab1/COPS5 were associated with disease-free survival and overall survival. The Jab1/COPS5 level was found to be a possible biomarker for clinical response to chemotherapy in lung cancer patients and for postoperative relapse in breast cancer patients who received adjuvant chemotherapy. In conclusion, this study identified Jab1/COPS5 as novel prognostic markers for lung cancer and breast cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22146

Publication Alerts

Research Papers:

Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients

Abstract